the third middle east and north africa immuno …

MIOF III THE THIRD MIDDLE EAST AND NORTH AFRICA

IMMUNO-ONCOLOGY FORUM MIOF -3 American University of Beirut Medical Center

05 - 06 November 2021 | Beirut - Lebanon

in collaboration with King Hussein Cancer Foundation & Center

MIOFMiddle East and North Africa Immuno-Oncology Forum

WELCOME LETTER

Dear Colleagues,

It gives me great pleasure to introduce to you the “Third Middle East and North Africa Immuno-Oncology Forum MIOF -II” which will be held on November 5-6, 2021 in its Virtual format at the American University of Beirut Medical Center , Beirut, Lebanon. MIOF is designed to tackle all aspects of Immuno-oncology practices in the different types of cancer. The conference features leaders in the field of Hematology - Oncology as well as certified healthcare professionals, pharmacists and Nurses, who will provide interactive scientific sessions that includes various diagnostic and therapeutic advancements in immune-oncology. The conference is an initiative to unite the diverse research and business communities working in this field under one roof to explore different aspects of immuno-oncology; bundled in one platform for all the oncologists, hematologists, research scholars and students to exchange their knowledge.From Breast, Lung, GI, GU to Malignant Hematology , the program will cover the most effective initiatives and best practices across the full spectrum of cancer treatment. This event is an effort to understand the underlying biological procedures which are amended to increase effectiveness, precision, survivability and quality of life. I am confident the conference will represent a stimulus to further harmonize our standards of practice and will hopefully lead to a culture change in the standard of care for Hematology oncology patients to improve their outcomes. Looking forward to a successful and fruitful congress and hoping to see you all there!


THE THIRD MIDDLE EAST AND NORTH AFRICAIMMUNO-ONCOLOGY FORUM MIOF -3American University of Beirut Medical Center

in collaboration with King Hussein Cancer Foundation and Center

PROGRAM OVERVIEW

MIOF is designed to tackle all aspects of Immuno-oncology practices in the different types of cancer, be it solid or Liquid. The forum features leaders in

the field of Hematology - Oncology as well as certified healthcare professionals, pharmacists and nurses, who will provide interactive scientific

sessions that includes various diagnostic and therapeutic advancements in immune-oncology.

The forum is an initiative to unite the diverse research and business communities working in this field under one roof to explore different aspects of

immuno-oncology; Bundled in one platform for all the oncologists, hematologists, research scholars and students to exchange their knowledge; From

Breast, Lung, GI, Prostate, Ovarian to Malignant Hematology, the program will cover the most effective initiatives and best practices across the full

spectrum of cancer treatment.

Hazem Assi, MDActivity Chair




ORGANIZING COMMITTEE

Hazem Assi, MD (Chair, AUBMC)

Jean El Cheikh, MD (Co-Chair, AUBMC)

Kamal El Rabih, MD (Co-Chair, KHCC)

PROGRAM OBJECTIVES

- Selection of candidate patients for immunotherapy

- Designing road maps for therapy and treatment plans

- Define best modalities of combined or single agent immunotherapies for defined conditions

- Evaluate variability and benefits versus disadvantages of immunotherapy aspects compared to other treatment approaches

- Investigate side effects and toxicities related to immunotherapies and discuss recovery modalities and control strategies

- Create a platform of collaboration between different disciplines for the continuity and standard of care




FRIDAY NOVEMBER 5, 2021

10:00 - 10:30 OPENING CEREMONY10:00 - 10:05 Hazem Assi, MD | Activity Director 10:05 - 10:10 Ali Taher, MD | Director Of Naef K. Bassile 10:10 - 10:15 Hikmat Abdel-Razeq, MD I CMO King Hussein Cancer Center10:15 - 10:20 Raymond Sawaya, MD | Dean Faculty Of Medicine10:20 - 10:25 Fadlo R. Khuri, MD | President Of American University Of Beirut

Moderator: Mohamed Kadri, MD10:30 - 11:15 Symposium Pierre Fabre Exploring The Value Of Navelbine Oral: Taking Care Of MBC Patients Today

10:30 - 10:55 Optimal Chemotherapeutic Choices In Metastatic Breast Cancer | Hamdy Abdel Azim, MD 10:55 - 11:10 Clinical Cases For Navelbine Oral In MBC | Fadi Farhat, MD 11:10 - 11:15 Q&A

11:15 - 11:35 Special Lecture: My Journey & My Story With Immunotherapy: A Patient Perspective Mr. Gerard Tufenkjian





12:15 - 12:25 Break

12:25 - 12:55 Symposium Astra Zeneca Immunotherapy: A Turning Point In The Management Of Unresectable Stage III NSCLC | Kamal Al-Rabi, MD

Moderator Hazem Assi, MD12:55 - 13:40 Symposium Pfizer Set A New Standard For mOS In UC | Sally Tamraz, MD

13:40 - 14:10 Symposium Lilly Optimizing Treatment For ER+ mBC Patients With Aggressive Disease | Georges Chahine, MD




11:35 - 12:15 SESSION I: NEW CONTRIBUTORS IN IMMUNO-ONCOLOGY Moderators: Hikmat Abdel-Razeq, MD - Humaid Al Shamsi, MD

11:35 - 11:55 Effectiveness Of COVID-19 Vaccination In Cancer Patients | Abdul Rahman Bizri, MD11:55 - 12:15 The Emerging Importance Of Molecular Tumor Board (MTB) | Rami Mahfouz, MD


14:10 - 15:10 SESSION II: IMMUNOTHERAPY IN THE CURATIVE SETTING Moderators: Khaled Ibrahim, MD - Joseph Makdessi, MD14:10 - 14:30 New Options In Triple Negative Breast Cancer (TNBC) | Hikmat Abdel-Razeq, MD14:30 - 14:50 New Treatment & Novel Approaches In Bladder Cancer | Joaquim Bellmunt, MD14:50 - 15:10 Rationale For Integrating Immunotherapy In Curative Treatment Protocols For Head & Neck Cancer | Ghazi Nsouli, MD

15:10 - 15:40 Symposium Novartis Advances In HR+ HER2- ABC | Hazem Assi, MD

Moderator: Iman Abou Dalle, MD15:40 - 16:10 Special Lecture: Patient Access To Immuno-Oncology Therapies & Country Inequalities | Vincent Rajkumar, MD

16:10 - 16:20 Break





16:20 - 17:30 SESSION III: IMMUNOTHERAPY IN THE METASTATIC SETTING Moderators: Hampig Kourie, MD - Kamal Alrabi, MD - Ziad Salem, MD

16:20 - 16:30 Does Our Patient Really Benefit From Treatment? From A Patient’s Perspective | Mrs. Victoria Ghazzal16:30 - 16:50 Liver Cancer: Benefitting From Increasing Choices Of Treatment Option | Ghassan Abou-Alfa, MD16:50 - 17:10 Evolving Immuno-Oncology Options In Metastatic NSCLC and SCLC | Arafat Tfayli, MD17:10 - 17:30 Implementation Of Immunotherapy In The First-line Treatment Of Esophageal, Gastroesophageal Junction & Gastric Cancers Rola Amarin, MD

17:30 - 18:00 Symposium Astra Zeneca IMFINZI: An Unprecedented Progress Offered For 1L ES-SCLC Patients | Fadi Farhat, MD

18:00 - 18:30 Symposium Lilly Treatment Landscape & Management Of Patients With EGFR Mutated NSCLC | Hazem Assi, MD




SATURDAY NOVEMBER 6, 2021 PARALLEL 1




09:00 - 09:30 Symposium MSD Redefining Survival Expectation In Frontline Metastatic Non-small Cell Lung Cancer | Hazem Assi, MD

09:30 - 10:00 Symposium Roche Immunotherapy Advances In The Management Of First Line Hepatocellular Carcinoma | Ali Shamseddine, MD

10:00 - 12:00 SESSION IV: LANDMARK STUDIES, CLINICAL PRACTICE AND GUIDELINES Moderators: Christina Khater, MD - Marwan Ghosn, MD

10:00 - 10:30 Lung Cancer Update | Suresh Ramalingam, MD 10:30 - 11:00 Breast Cancer Update | Nagi El Saghir, MD11:00 - 11:30 GI Malignancy Update | Ali Shamseddine, MD11:30 - 12:00 GU Cancer Update | Deborah Mukherji, MD

12:00 - 12:30 Symposium BMS The Future Is Now: Transforming The Management Of Gastric Cancer With Immuno-Oncology | Francois Kamar, MD

SATURDAY NOVEMBER 6, 2021

12:30 - 17:30 SESSION V: HEMATOLOGY

Moderator Colette Hanna, MD

12:30 - 13:00 Symposium Takeda ADCETRIS ON THE FRONT-LINE Managing Patients With CD30+ HL | Nabil Chamseddine, MD

Moderator Mouin Moubarak, MD13:00 - 13:30 Symposium Amgen Management Of RRMM Patients After The First Relapse | Jean El Cheikh, MD 13:30 - 13:40 Break

Moderators Alessandro Isidori, MD - Hady Ghanem, MD13:40 - 14:20 Acute Leukemia Session 13:40 - 14:00 The Treatment Of ALL in 2021 | Hagop Kantarjian, MD14:00 - 14:20 Management Of Acute Myeloid Leukemia Relapsing After An Allogeneic Hematopoietic Cell Transplant: A True Therapeutic Challenge | Mohamad Kharfan Dabaja, MD




Moderator Jean El Cheikh, MD14:20 - 14:50 Symposium Abbvie Transformation To A New ERA In CLL With Venetoclax | Mirvat Matar, MD

Moderators Ahmad Ibrahim, MD 14:50 - 15:10 Lymphoma Session

New Advances In The Lymphoma Treatment | Anna Sureda, MD

Moderator Tarek Wehbe, MD15:10 - 15:40 Symposium Sandoz Biosimilar In Non-Hodgkin’s Lymphoma: Time To Make The Change | Iman Abu Dalle, MD

15:40 - 15:50 Break

Moderators Ali Bazarbachi, MD - Roberto Crocchiolo, MD15.50 - 16.30 Cellular Therapy Session

15:50 - 16:10 CAR-T And Regulation Process | Christian Chabannon, MD16:10 - 16:30 CART In Clinical Practice | Ibrahim Yakoub Agha, MD





Moderator Dr. Marcel Massoud16:30 - 17:00 Symposium Pfizer Jean El Cheikh, MD

17:00 - 17:30 Symposium Janssen Take Control In Frontline CLL. | Georges Chahine, MD






PARALLEL 209:15 - 11:45 NURSING SESSION

Moderator: TBA09:15 - 09:30 Welcome & Introduction | Nariman Iskandarani TIBI, MSN, RN 09:30 - 10:00 How Dose Immunotherapy Utilize Our Immune System To Attack Cancer Cells | Shirin Abdullah Mohammad Yacoub, BSN10:00 - 10:30 The Good, The BiTE, & The Ugly | Ammar Zahreddine, MScN, RN10:30 - 11:00 Immunotherapy In Combination With Chemotherapy? When & Why? | Fathi Tayseer Abdalal, MSN, BSN11:00 - 11:30 Case Presentations In Immunotherapy: Most Common Side Effects & Their Management | Houry Kazarian, BSN, RN11:30 - 11:45 Questions & Answers & Evaluation | Rebecca El-Asmar, MSN, RN, AOCNS

PARALLEL 310:00 - 11:30 PHARMACY SESSION | PHARMACOTHERAPY UPDATES

Moderator: Rony Zeenny, Pharm.D., MPH, BCPS-AQ ID, FASHP10:00 - 10:30 Bispecifc T Cell Engagers: An Emerging Therapy For Management Of Hematologic malignancies | Fatima Ismail, R.Ph10:30 - 11:00 Association Between The Occurrence Of Immune-Related Adverse Events With Efficacy Of Checkpoint Inhibitors In Cancer Patients | Alissar Ghaddar, Pharm.D MBA, BCOP11:00 - 11:30 The Pharmacist’s Role In Managing Immune-Therapy Related Toxicity | Aline Hajj, Pharm.D., Ph.D.




Organized by: 4th Floor, Qubic CenterDaoud Ammoun StreetHorsh Tabet - Sin El FilP.O. Box: 90-361 BeirutTel: +961 1 510880/1/2/3 Mobile: +961 71 103123

[email protected] | www.infomedweb.com

LEBANON UAE

| |DMCC Business CentreAlmas TowerJumeirah Lakes Dubai, United Arab EmiratesUnit No: 3820Mobile: +971 50 9110475

Mezzanine floor,Aliya ComplexSalem Al Mubarak St Block 2, Salmiya - KuwaitTel: +965 6556 7669

KUWAIT

Oncology

Organized by

Continuing Medical Education OfficeE: [email protected]: http://cme.aub.edu.lb

the third middle east and north africa immuno …

Documents